{
  "docId": "019de075-a698-70b1-b3ba-29e176396a9c",
  "docSlug": "63ec8e773c9b43e7b033b64167026114",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 52 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 52,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a698-70b1-b3ba-29e176396a9c/18",
  "deckHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c",
  "deckJsonHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c.json",
  "deckAnchorHref": "/decks/019de075-a698-70b1-b3ba-29e176396a9c#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.02,
        "y": 0.58
      },
      "kind": "chart",
      "text": "Hematologic Cancers Market Size",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "058227d6-b689-48d9-b386-ac08bb2de936",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.02,
        "y": 0.38
      },
      "kind": "list",
      "text": "Multiple Myeloma (“MM”) is 3rd most common blood cancer, impacting 176,404 patients annually, with life expectancy of 5 years. AL Amyloidosis is developed by 14,982 people annually—with no available treatments as standard of care.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "006300f1-249b-45f1-a9ee-8b620215ba2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.52,
        "y": 0.3
      },
      "kind": "list",
      "text": "1. Leveraging market CAR-T experience so far. 2. Demand for MM CAR-Ts exceeds supply. 3. Still common with approved CAR-Ts: High grade Cytokine Release Syndrome. 4. Bispecifics/Allogeneic CAR-Ts still work in progress.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42eac604-b3f1-4423-a759-8ff94d630d72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.02,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "Hematologic cancers market opportunity is $60bn today growing to $120bn in 2028.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15fe42c0-3253-4a6f-826e-dd54b17e9cd1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Sources: Multiple Myeloma life expectancy source - Arcellx July 2022 investor presentation... (etc)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a13b2ee5-b81b-4f61-b0ab-a494c2279998",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.52,
        "y": 0.75
      },
      "kind": "table",
      "text": "NXC-201 vs Allogeneic BCMA-CAR-T vs BCMA bispecific engagers clinical data",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78ed0674-690e-4dd3-9203-e241366dd400",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "NXC-201 Entering Large Markets At a Pivotal Moment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f5fb21a-60a4-416b-835f-dd727ce19396",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "why_now",
      "slug": null,
      "matchId": "c806c1eb-de1b-4751-b0f3-6c581e644eb6",
      "evidence": "The slide explicitly uses a 'Why Now' section to justify market entry timing.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 23,
      "from": 10,
      "beatId": "b4eaa88f-5d19-4a97-bcad-d3506fb7e4a8",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Presentation of NXC-201 and IMX-110 as innovative therapies",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 15,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "ec7f8eed-93e3-495e-a456-08be8d6fdcb8",
      "evidence": "NXC-201 entering large markets at a pivotal moment",
      "position": 1,
      "objective": "Why now for Immix Biopharma's therapies?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}